Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the company's progress with its Stage 2 pivotal GaRP irritable bowel syndrome trial.

The company has made good strides with recruitment for the trial, with over 30 participants enrolled and approximately 20 potential participants currently in the final screening to determine suitability for enrolment.

The company has added additional sites in Adelaide and the Sunshine Coast, while it is receiving sustained levels of interest at existing sites in Melbourne, Sydney, and Brisbane.

The Stage 2 trial is designed to confirm the highly encouraging and clinically meaningful interim results from Stage 1 of the GaRP-IBS clinical trial. 

GaRP is considered to have the potential to be a disease-modifying treatment that aims to positively impact a substantial proportion of the population suffering from the debilitating symptoms of digestive disorders, including irritable bowel syndrome.

Anatara recently received more than $626,000 from the Australian Taxation Office under the Federal Government’s Research and Development (R&D) tax incentive scheme for FY2024. 

Those funds will support Phase 2 of the clinical trial of GaRP.

Articles:
https://smallcaps.com.au/anatara-lifesciences-on-track-recruitment-stage-2-garp-ibs-trial/
https://smallcaps.com.au/anatara-lifesciences-stage-2-garp-trial-ibs-treatment-gains-momentum/

For more information on Anatara Lifesciences:
https://smallcaps.com.au/stocks/asx-anr/